EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online June 5, 2008
Experimental Biology and Medicine 233:1026-1034 (2008)
doi: 10.3181/0801-RM-19
© 2008 by the Society for Experimental Biology and Medicine
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
233/8/1026    most recent
0801-RM-19v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, J. J.
Right arrow Articles by Jin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, J. J.
Right arrow Articles by Jin, M.

ORIGINAL RESEARCH ARTICLE

Blockade of Atopic Dermatitis-Like Skin Lesions by DA-9102, a Natural Medicine Isolated from Actinidia arguta, in the Mg-Deficiency Induced Dermatitis Model of Hairless Rats

Jeong June Choi*, Bokyoung Park*, Dong Hee Kim*, Myoung-Yun Pyo{dagger}, Sangzin Choi{ddagger}, Miwon Son{ddagger} and Mirim Jin*,1

* Lab of Pathology, College of Oriental Medicine, Daejeon University, Daejeon, 300-716, Korea; {dagger} College of Pharmacy, Sookmyung Women’s University, Yongsan Ku, 140-742, Seoul, Korea; and {ddagger} Dong-A Co. Ltd., R&D Center, Yongin, Gyeonggi-do, 449-905, Korea

To whom requests for reprints should be addressed at 1 Lab of Pathology, College of Oriental Medicine, Daejeon University, #96-3 Yongun-dong Dong-gu, Daejeon, Korea, 300-716. E-mail: mirimj{at}dju.ac.kr

DA-9102 isolated from Actinidia arguta is a candidate of natural medicine currently under Phase II clinical trial for atopic dermatitis in Korea. In this study, spontaneous dermatitis was induced by magnesium deficiency in hairless rats and this system was applied to assess the suppressive effects of DA-9102 on atopic dermatitis-like skin disease. Oral administration of DA-9102 at a dose of 100 mg/kg for 16 days substantially suppressed the occurrence of spontaneous dermatitis. Eczematous skin lesions, water loss and scratching behavior were significantly decreased by DA-9102 in a dose-dependent manner. Infiltration of inflammatory cells into the skin and pathologic remodeling of the epidermis and dermis were much less than the Mg-def. group. Results from flow cytometry analysis of peripheral blood mononuclear cells indicated that DA-9102 suppressed activation of leukocytes. The decrease in the number of CD45RA+ cells was accompanied by a lower level of IgE in DA-9102 treated rats, and the reduction in the number of CD11b+ cells by DA-9102 in both periphery and skin was significant. Further, DA-9102 not only suppressed the mRNA expression of TH2 cytokines including IL-4 and IL-10 in the lymph node but it also decreased the levels of inflammatory mediators such as nitric oxide and leukotriene B4 (LTB4) in the serum. Taken together, these results suggest that DA-9102 is an orally applicable potent immune modulator capable of controlling the occurrence of atopic dermatitis-like skin disease.

Key Words: Actinidia arguta • DA-9102 • hairless rat (OFA hr/hr) • immune modulator • Mg-deficiency induced dermatitis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Experimental Biology and Medicine.